1. Catalog
  2. Medical Considerations for Patients with Opioid Us ...
Image For Activity Cover
Medical Considerations for Patients with Opioid Use Disorder
SUD 101 Core Curriculum Overview

Curriculum overview:  While healthcare professionals are often on the front lines of treating substance use disorders, most have limited (if any) training in this area. The SUD 101 Core Curriculum was created to provide a foundation of the current research, resources, and support needed to increase healthcare professionals’ competence and confidence in the care of their patients across the continuum of care. This activity, Medical Considerations for Patients with Opioid Use Disorder, is part of the 23-module curriculum. Please see below for a summary of module 14 out of 23:
Module 14 Overview
Title: Medical Considerations for Patients with Opioid Use Disorder 

Presenter(s): Jeanette M. Tetrault, MD, Professor of Medicine and Public Health, Yale School of Medicine

Module Description: Medical complications are common among patients with opioid use disorder. Signs and symptoms of acute or chronic infectious diseases often prompt patients to seek medical care. The time of presentation for complications related to injection drug use present an opportunity to screen and employ early intervention strategies for other complications, engage individuals in addiction treatment and implement harm reduction. This module reviews features of skin and soft tissue infections among people who inject drugs, reviews risk factors for Hepatitis C (HCV) and HIV, describes prevention interventions for HCV and HIV, and discusses treatment approaches for HCV and HIV in patients with opioid use disorder. 

Educational Objectives:

  • Recognize acute and chronic injection-related infections related to substance use.
  • Define epidemiologic trends of injection drug use related infective endocarditis (IDU-IE) in the US.
  • Consider treatment-seeking for complications for substance use as an opportunity for healthcare teams to engage individuals in addiction treatment and implement harm reduction strategies.
  • Review treatment and prevention opportunities for healthcare teams to address Hepatitis C (HCV) and HIV in patients with substance use disorder
Summary
Availability: On-Demand
Expires on Jan 12, 2026
Cost: FREE
Credit Offered:
1 CME Credit
1 PA-CME Credit
1 Other Professionals Credit
1 Nursing Credit
1 Pharmacy Credit
1 IPCE Credit
Create Account
Recommended
 
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.


Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 and grant no. 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
8-Hour DEA Training Inquiries, email PCSS-MOUD.

ORN
opioidresponsenetwork.org
Powered By